Webinar: Active Hemovigilance Results for INTERCEPT - Review of Multi-Year Studies Presentated at International Hemovigilance Seminar (IHS)
In this brief webinar, Dr. William Reed, Director of Clinical Research and Medical Affairs at Cerus Corporation, outlines several of the key INTERCEPT presentations from the 12th International Hemovigilance Seminar (IHS), held in Dubrovnik, Croatia, February 17 -19, 2010. The IHS meeting was an opportunity for hematologists and epidemiologists to review current global and regional trends in transfusion safety. Investigators from multiple independent blood centers in Sweden, Belgium, France and Slovenia shared extensive multi-year safety data with routine use of the INTERCEPT Blood System for platelets and plasma. Citing decreased adverse transfusion reactions compared to conventional platelet components, the observations from these active hemovigilance efforts serve to confirm and extend the safety profile for INTERCEPT. Dr. Reed covers the highlights of these presentations including the following:
- 3-year EFS Alsace platelet experience: n=42,465
- 6-year Mont-Godinne experience: evaluation of central nervous system bleeding before and after the introduction of INTERCEPT
- Multi-site European HV experience: n=18,641
INTERCEPT is beginning to introduce a new paradigm in transfusion medicine – beyond pathogen inactivation:
- Improvements in shelf life, wastage, & platelet availability
- Reduction in complexity, product loss, regulatory risk, and residual risk for septic transfusion reactions
- All products with residual CMV risk removed
- All rare platelet donors now functionally ‘CMV-negative’
- All products functionally ‘TA-GVHD-safe’
- Cost and logistics become favorable with scale & routine use
Note: The INTERCEPT Blood System is CE Marked in Europe as a Class III medical device. The INTERCEPT Blood System is not approved in the United States.
William F. Reed, M.D.
Director, Clinical Research and Medical Affairs
Concord, California, USA
William F. Reed, M.D. received his medical degree from Brown University. He completed fellowships in Pediatric Hematology/Oncology at Children’s Hospital and Research Institute in Oakland and in Transfusion Medicine at Blood Centers of the Pacific in San Francisco. Prior to joining Cerus in late 2009, he was an Investigator for ten years at Blood Systems Research Institute in San Francisco. Dr. Reed has been a faculty member at the University of California San Francisco School of Medicine where he was the first Medical Director and helped to establish the University’s Human Islet and Cellular Transplantation Laboratory. Dr. Reed has also served as Medical Director for the Northern California Region of the American Red Cross. His research interests include hemoglobinopathies, placental blood banking & transplantation and leukocyte microchimerism following transfusion. At Cerus, he is also taking a special interest in the causes and treatment of anemia in the developing world.
View INTERCEPT IHS Abstracts
Back to webinar page